Company Overview of Dr. Reddy's Laboratories Limited
Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients (APIs) and intermediates, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services; and manufactures and sells APIs and steroids in acco...
8-2-337, Road No. 3
Founded in 1984
Key Executives for Dr. Reddy's Laboratories Limited
Co-Chairman, Chief Executive Officer, Managing Director and Member of the Management Council
Total Annual Compensation: 8.3M
Chairman of the Board and Member of the Management Council
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2016.
Dr. Reddy's Laboratories Limited Key Developments
Dr. Reddy's Laboratories Announces US District Court's Opinion Relating to Patent Infringement
Feb 16 17
Dr. Reddy's Laboratories Ltd. announced that, the United States District Court for the District of New Jersey issued its opinion regarding Helsinn Healthcare's patent infringement claims against Dr. Reddy's Laboratories' proposed palonosetron product, pursuant to a "paper" NDA under Section 505(b)(2) of the Food, Drug and Cosmetic Act. The court found that Dr. Reddy's proposed palonosetron hydrochloride 0.25 mg /5 ml product infringes certain claims of U.S. Patent Nos. 7,947,724, 8,729,094 and 9,066,980, and that the asserted claims of the '094 and '980 Patents were not invalid.
Dr. Reddy's Laboratories Limited Announces Unaudited Consolidated Cash Flow Earnings Results for the Nine Months Ended December 31, 2016
Feb 10 17
Dr. Reddy's Laboratories Limited announced unaudited consolidated cash flow earnings results for the nine months ended December 31, 2016. For the nine months, the company reported net cash from operating activities of INR 12,996 million against INR 31,991 million a year ago. Expenditure on property, plant and equipment was INR 9,325 million against INR 8,709 million a year ago. Expenditure on other intangible assets was INR 28,307 million against INR 2,606 million a year ago.
BioMarin Pharmaceutical Inc. Sues Dr. Reddy's Laboratories Ltd. to Stop Generic Version of its $90,000 Year Drug
Feb 6 17
BioMarin Pharmaceutical Inc. said that on February 6, 2017 in U.S. District Court in New Jersey that a version of the drug Kuvan by Dr. Reddy's Laboratories Ltd. infringes on six BioMarin patents. The Indian company late last year asked the Food and Drug Administration to approve its powder version of Kuvan, saying that BioMarin's patents are invalid, unenforceable or will not be infringed by manufacturing, use or sale. BioMarin's suit does not ask for a specific award amount, but the company asks for "monetary relief together with interest" as well as attorneys' fees, costs and expenses of the suit and any award the court would add. Suits between brand-name drug developers and generic drug makers are not unusual; in fact, there is a whole system of rules that both types of companies must follow. But the stakes are high for BioMarin, since Kuvan is a one-of-its-kind drug with an average price of $90,000 a year. Kuvan is dosed by the weight of the patient, and its typical users are children, so as patients get older and weigh more, the annual cost of the drug increases. Through the first three quarters of last year, Kuvan was BioMarin's second-best-selling drug with $258 million in revenue. That was 47% higher than the same period in 2015. Dr. Reddy's is the second generic drug maker to attempt to sell a powder version of Kuvan. Par Pharmaceutical Cos. Inc. that earlier had sought to market Kuvan tablets, was sued in February 2016 by BioMarin. That case is ongoing.
Similar Private Companies By Industry
Recent Private Companies Transactions